Stockreport

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

ObsEva SA - Common Shares  (OBSV) 
Last obseva sa - common shares earnings: 3/5 01:00 am Check Earnings Report
PDF Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleed [Read more]